Peptide Atlas — health, wellness & peptide resources
Peptide Library
Metabolic Health & Weight Management

Cagrilintide

Also referenced as: AM833, long-acting amylin analogue

A long-acting amylin analogue studied alone and in combination with semaglutide.

Evidence grade
CEarly Human Research

Early Human Research

Regulatory status
Clinical Trials
Human data
Yes

Registered clinical trials exist

Last reviewed
September 1, 2026

Overview

Amylin is co-secreted with insulin and contributes to meal termination. Cagrilintide is a modified, long-acting amylin analogue designed for weekly administration.

Most attention concerns the fixed combination with semaglutide, studied on the premise that two distinct satiety pathways may add together.

Why It's Being Studied

  • Satiety signalling independent of the incretin pathway.
  • Whether combining amylin and GLP-1 agonism improves weight outcomes over GLP-1 alone.

Mechanism of Action

In plain language

It imitates a hormone released with insulin that helps signal the end of a meal and slows how quickly the stomach empties.

Technical detail

Cagrilintide is an acylated analogue of human amylin with non-selective activity at calcitonin and amylin receptor complexes (AMY1–3). Signalling in the area postrema and nucleus accumbens is implicated in reduced food intake, with slowed gastric emptying as a peripheral contributor.

Research Areas & Routes Studied

Areas studied
  • Body weight
  • Appetite regulation
  • Glycaemic control
Routes used in research
  • Subcutaneous injection (in clinical trials)

Evidence Summary

Early and mid-phase human trials exist, mostly as part of a combination product, with limited standalone long-term data.

Human clinical evidence

  • Phase 1b and phase 2 trials reported dose-dependent weight reduction with weekly cagrilintide.
  • Combination trials with semaglutide reported greater weight reduction than either component in the studied populations.

Clinical trials

  • Later-phase combination programmes were ongoing at last review.

Reported Adverse Events in Research

  • Nausea and other gastrointestinal effects.
  • Injection-site reactions.
  • Long-term safety data are limited.

Limitations of Current Evidence

  • Standalone evidence is thinner than combination evidence.
  • No approval and no established clinical dosing outside trials.

Research References

  • Phase 2 trial

    Cagrilintide for weight management: phase 2 randomised trial

    Main finding
    Dose-dependent weight reduction versus placebo over 26 weeks.
    View Study
  • Regulatory document

    Registered cagrilintide trials

    View Clinical Trial
This page is an educational research summary. It is not medical advice, does not recommend human use, and does not provide individualised dosing. Many compounds discussed here are research use only and are not approved medicines.